Big question for Pfizer: Will Enbrel’s EU biosim bring on the pain?

Carly Helfand

Amgen and 's Enbrel officially has a biosimilar rival in Europe. And if the rollout goes anything like the recent EU launch of Remicade copy Remsima, the blockbuster brand will be in trouble.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS